

INNOVATE 2 REQUEST FOR PROPOSAL (RFP): CABOTEGRAVIR LONG ACTING FOR PREVENTION

SUMMARY

Purpose

ViiV Healthcare is committed to supporting research efforts of HIV and Medical communities and is announcing a Request for Research Proposals for Investigator Sponsored Studies (ISS). This is your opportunity to apply for a research award from ViiV Healthcare to address the knowledge gaps and research priorities for **Cabotegravir Long Acting for prevention**.

Objective

We are seeking proposals for clinical research studies within specific areas of interest. Successful proposals will receive financial support to undertake independent research through our ISS programme.

Research priority areas

The INNOVATE 2 RFP has three research priority areas ('Areas of Interest') for scientific data on **Cabotegravir Long Acting for prevention**.

1	<p><u>Real-world use and impact on overall PrEP uptake and overall patient health in broad populations:</u></p> <p>Example research questions, but not limited to: Does offering CAB LA for PrEP to broad populations result in</p> <ul style="list-style-type: none"> a) Increased overall PrEP uptake, adherence and/or persistence. b) A neutral or positive impact on tolerability (incl. metabolic, bone + renal markers) compared to oral PrEP options.
2	<p><u>Strategies to improve awareness of PrEP and identification of barriers and facilitators related to CAB LA for PrEP uptake:</u></p> <p>Example research questions, but not limited to:</p> <ul style="list-style-type: none"> a) How can awareness be increased in people who have never used PrEP and how can they be connected to PrEP services? b) What specific tools or settings promote identification of PWBP and/or facilitate the conversation around HIV PrEP options? c) What are the key drivers or barriers related to uptake of CAB LA for PrEP? And what strategies can be employed to address barriers?
3	<p><u>Optimise implementation and/or scale up of CAB LA for PrEP:</u></p> <p>Example research questions, but not limited to:</p> <ul style="list-style-type: none"> a) [US only] Understanding how same day/rapid start of CAB LA for PrEP can be facilitated including HIV testing approach and how it enables uptake. b) [Brazil, Canada, France, Italy, Spain, UK only] Which specific health-delivery sites outside of clinical centers demonstrate optimized implementation of CAB LA for PrEP? <p>Possible examples of health delivery settings could include pharmacies, mobile health clinics, family planning centers, University clinics, mobile health clinics, home/district nurses, telehealth services, campus health clinics</p>

Timeline



Applicants

Applicants must be affiliated with a clinical or academic institution and are strongly encouraged to partner with a researcher(s) with clinical experience in the field of HIV and a proven track record of conducting Investigator Sponsored Studies. The study setting(s) can include a variety of healthcare and academic institutions.

Applicants must provide their CV or biosketch, stating relevant experience which will be uploaded as part of the application process.

For Investigator sponsored studies (ISS), the product is required to be registered and available in the country to be able to support a study (i.e., reimbursement in place).

If the drug is being used as part of the study, ViiV Healthcare will not supply the drug. It must be available in participating countries at study start.

List of Countries eligible to participate:

- North America: US, Canada
- Europe: Spain, Italy, France, United Kingdom
- International Region: Brazil

Note: Due to the real-world nature of the priority areas included in this RFP, drug supply requests are not included in this RFP

For detailed information or to submit a concept, visit ISS.viivhealthcare.com

If you have any questions, please submit these to your local ViiV Healthcare medical contact or to: vh.rfp-admin@viivhealthcare.com